X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (165) 165
male (142) 142
female (135) 135
middle aged (117) 117
index medicus (107) 107
cardiac & cardiovascular systems (98) 98
aged (96) 96
adult (57) 57
mortality (48) 48
treatment outcome (40) 40
medicine, general & internal (39) 39
abridged index medicus (34) 34
acute coronary syndromes (34) 34
heart attacks (34) 34
myocardial infarction (31) 31
risk factors (31) 31
coronary heart disease (30) 30
therapy (30) 30
care and treatment (28) 28
drug therapy (28) 28
myocardial-infarction (28) 28
stroke (28) 28
management (27) 27
acute coronary syndrome - drug therapy (26) 26
clinical neurology (26) 26
double-blind method (26) 26
medical and health sciences (25) 25
medicin och hälsovetenskap (25) 25
outcomes (24) 24
risk (24) 24
cardiovascular (23) 23
cardiovascular disease (22) 22
clinical medicine (22) 22
magnetic resonance imaging (22) 22
clopidogrel (21) 21
follow-up studies (21) 21
klinisk medicin (21) 21
time factors (21) 21
electrocardiography (20) 20
peripheral vascular disease (20) 20
platelet aggregation inhibitors - therapeutic use (20) 20
cardiac and cardiovascular systems (19) 19
clinical trials (19) 19
kardiologi (19) 19
myocardial infarction - drug therapy (19) 19
patient outcomes (19) 19
psychiatry (19) 19
aged, 80 and over (18) 18
aspirin (18) 18
cardiac patients (18) 18
hemorrhage - chemically induced (18) 18
myocardial infarction - mortality (18) 18
prospective studies (18) 18
trial (18) 18
analysis (17) 17
heart attack (17) 17
thrombolytic therapy (17) 17
atrial fibrillation (16) 16
atrophy (16) 16
diagnosis (16) 16
disease (16) 16
ischemia (16) 16
risk assessment (16) 16
thrombolysis (16) 16
acute myocardial-infarction (15) 15
cardiology (15) 15
patients (15) 15
prognosis (15) 15
acute coronary syndrome (14) 14
age factors (14) 14
coronary artery bypass (14) 14
events (14) 14
mri (14) 14
research (14) 14
severity of illness index (14) 14
anticoagulants (13) 13
anticoagulants - therapeutic use (13) 13
cardiovascular diseases (13) 13
drug therapy, combination (13) 13
fibrinolytic agents - therapeutic use (13) 13
health aspects (13) 13
prevention (13) 13
surgery (13) 13
coronary angiography (12) 12
coronary artery disease (12) 12
death (12) 12
guidelines (12) 12
proportional hazards models (12) 12
secondary prevention (12) 12
thrombin (12) 12
unstable angina (12) 12
usage (12) 12
atherosclerosis (11) 11
diabetes (11) 11
evaluation (11) 11
heart diseases (11) 11
heart failure (11) 11
kaplan-meier estimate (11) 11
myocardial infarction - epidemiology (11) 11
ophthalmology (11) 11
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
UofT at Mississauga - Stacks (2) 2
Gerstein Science - Stacks (1) 1
Institute for Christian Studies - Stacks (1) 1
Knox College (Caven) - Stacks (1) 1
Regis College - Stacks (1) 1
Royal Ontario Museum - Far Eastern Egyptian (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Trinity College (John W Graham) - Wycliffe Storage (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Full text | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2016, Volume 37, Issue 20, pp. 1591 - 1602
Aims Thromboembolic risk stratification schemes and clinical guidelines for atrial fibrillation (AF) regard risk as independent of classification into... 
Systematic review | Stroke | Thromboembolism | Atrial fibrillation | Meta-analysis | PREDICTING STROKE | PERSISTENT | CARDIAC & CARDIOVASCULAR SYSTEMS | ORAL ANTICOAGULATION | DEATH | THERAPY | WARFARIN | AF TRIAL | STRATIFICATION SCHEMA | CLINICAL-OUTCOMES | REGISTRY | Anticoagulants | Atrial Fibrillation | Humans | Risk Factors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 20 - 33
In this trial, vorapaxar, a protease-activated–receptor 1 antagonist that inhibits thrombin-induced platelet activation, was not effective in reducing the... 
MEDICINE, GENERAL & INTERNAL | PLACEBO | GLYCOPROTEIN IIB/IIIA INHIBITORS | CLOPIDOGREL | TASK-FORCE | SAFETY | DOUBLE-BLIND | ANTIPLATELET THERAPY | Follow-Up Studies | Angioplasty | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Combined Modality Therapy | Lactones - adverse effects | Lactones - therapeutic use | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Coronary Artery Bypass | Acute Coronary Syndrome - therapy | Aged | Hemorrhage - chemically induced | Antagonists (Biochemistry) | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Cardiovascular disease | Hemorrhage | Bleeding | Investigations | Manuscripts | Ischemia | Blood platelets | Acute coronary syndromes | Research centers | Malalties cardiovasculars | Bypass cardiopulmonar | Medicaments | Bypass cardiopulmonary | Plaquetes sanguínies | Cardiovascular diseases | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article